The Italian Medicines Agency (Agenzia Italiana del Farmaco AIFA) implemented the Negotiation of medicines: new simplified and fast-track procedures (Negoziazione farmaci: nuove procedure semplificate e fast-track) on 1 April 2026. This administrative update marks a definitive shift in the national pricing and reimbursement framework. It concludes the transition to a unified evaluation model following the merger of the previous binary committee structure. This procedural evolution centralises the decision-making flow within the Scientific-Economic Commission (Commissione Scientifico-Economica CSE). This body now manages the entire clinical and financial assessment process in a single stream.
The simplified procedure targets generic medicines, biosimilars, and certain line extensions. This mechanism reduces the evaluation window to 60 or 90 days – a significant decrease from the standard 180-day cycle. It applies when the proposed price is equal to or lower than existing reference products. By removing the need for exhaustive technical debate on established molecules, the regulator aims to release administrative capacity for more complex assessments. This streamlining facilitates the rapid entry of lower-cost alternatives to manage the national health budget.
The fast-track route prioritises medicines of significant clinical value. This specifically includes orphan medicinal products and innovative therapies. It also covers products offering substantial savings to the National Health Service (Servizio Sanitario Nazionale SSN). The CSE will now process these applications within a 100-day window. These data indicate that the regulator intends to resolve pricing bottlenecks early for high-priority therapies. Robert Nisticò, President of the Italian Medicines Agency, described the measure as a tangible sign of a new course for the agency. He noted that the objective is to reduce bureaucracy and ensure that life-saving treatments reach patients more quickly.
Pierluigi Russo, Director General of the Italian Medicines Agency, emphasised that simplification does not imply a reduction in technical rigour. He stated that the agency has defined clear, objective criteria to ensure that the quality of the scientific assessment remains high while the timelines contract. This measure intended to provide greater procedural certainty for manufacturers. The state now requires applicants to demonstrate eligibility for these priority tracks during the initial filing phase to avoid the standard administrative queue.
Implementation is immediate for all dossiers submitted from April 2026. The shift toward accelerated pathways will likely shorten the time-to-market for innovative products. It will also increase price pressure on established brands as generic entry becomes more predictable. Success now depends on the ability of manufacturers to align their submission strategies with the specific technical requirements of the CSE. This dual-track system forces a more strategic approach to dossier preparation – where clinical differentiation and economic value determine the speed of the negotiation process.
Source: Agenzia Italiana del Farmaco
Link: Negoziazione farmaci: nuove procedure semplificate e fast-track (Negotiation of medicines: new simplified and fast-track procedures)
Date: 1 April 2026
